Bruce L Innis Selected Research

NDV-HXP-S COVID-19 vaccine

10/2021

A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Bruce L Innis Research Topics

Disease

31	Human Influenza (Influenza) 02/2022 - 12/2009
14	Dengue (Dengue Fever) 01/2019 - 03/2002
12	Infections 03/2021 - 09/2002
8	Pain (Aches) 01/2022 - 11/2005
8	Viremia 07/2014 - 12/2002
6	COVID-19 03/2022 - 07/2020
6	Hepatitis E 11/2018 - 05/2002
4	Fever (Fevers) 03/2021 - 03/2008
3	Rubella (German Measles) 01/2017 - 08/2012
3	Mumps 01/2017 - 08/2012
3	Measles 01/2017 - 08/2012
3	Chickenpox 04/2014 - 08/2011
2	Headache (Headaches) 01/2022 - 01/2011
2	Fatigue 01/2022 - 01/2011
2	Whooping Cough (Pertussis) 01/2022 - 01/2021
2	Influenza in Birds (Avian Flu) 01/2021 - 07/2015
2	Narcolepsy 01/2019 - 01/2016
2	Virus Diseases (Viral Diseases) 01/2019 - 01/2019
2	Hepatitis A (Hepatitis, Infectious) 09/2013 - 08/2012
2	Exanthema (Rash) 01/2013 - 08/2012
1	Myalgia 01/2022
1	Diphtheria 01/2022
1	Tetanus 01/2022
1	Inflammation (Inflammations) 03/2021
1	Weight Loss (Weight Reduction) 03/2021
1	Lung Injury 03/2021
1	Respiratory Tract Infections (Respiratory Tract Infection) 01/2021
1	Asthma (Bronchial Asthma) 01/2020
1	Liver Diseases (Liver Disease) 11/2018
1	Pneumococcal Infections 11/2017
1	Paralysis (Palsy) 01/2014
1	Thrombocytopenia (Thrombopenia) 01/2014
1	Facial Paralysis (Facial Palsy) 01/2014
1	Ulcerative Colitis 01/2014
1	Celiac Disease (Celiac Sprue) 01/2014
1	Japanese Encephalitis 09/2013
1	Encephalitis (Encephalitis, Rasmussen) 09/2013
1	Hepatitis 03/2007
1	Intussusception 01/2006
1	Gastroenteritis 01/2006
1	Reinfection 09/2002
1	Consciousness Disorders 03/2002
1	Flavivirus Infections 03/2002

Drug/Important Bio-Agent (IBA)

61	VaccinesIBA 03/2022 - 05/2002
20	Influenza Vaccines (Influenza Vaccine)FDA Link 02/2022 - 12/2009
10	AntigensIBA 01/2021 - 08/2005
5	Neutralizing AntibodiesIBA 07/2008 - 04/2003
4	Hemagglutinins (Hemagglutinin)IBA 01/2021 - 04/2015
4	Dengue VaccinesIBA 01/2019 - 09/2013
4	EnzymesIBA 01/2017 - 05/2002
3	Combined VaccinesIBA 01/2018 - 12/2003
3	Inactivated VaccinesIBA 01/2018 - 04/2015
3	Immunoglobulin M (IgM)IBA 10/2006 - 03/2002
2	pertussis toxoidIBA 01/2022 - 01/2021
2	Anti-Bacterial Agents (Antibiotics)IBA 09/2020 - 01/2020
2	Proteins (Proteins, Gene)FDA Link 01/2019 - 03/2002
2	AS03 adjuvantIBA 06/2017 - 07/2015
2	Measles-Mumps-Rubella Vaccine (MMR Vaccine)IBA 01/2017 - 12/2015
2	ImmunosorbentsIBA 01/2017 - 12/2002
2	AntibodiesIBA 01/2017 - 01/2016
2	Detergents (Detergent)IBA 01/2016 - 07/2015
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 08/2014 - 07/2014
2	RNA (Ribonucleic Acid)IBA 06/2013 - 12/2002
2	Capsid Proteins (Capsid Protein)IBA 10/2006 - 05/2002
2	Attenuated VaccinesIBA 01/2006 - 08/2005
2	Immunoglobulin G (IgG)IBA 12/2002 - 03/2002
1	pertactin FDA Link 01/2022
1	Pertussis ToxinIBA 01/2022
1	COVID-19 VaccinesIBA 10/2021
1	NDV-HXP-S COVID-19 vaccineIBA 10/2021
1	Respiratory Syncytial Virus VaccinesIBA 01/2020
1	Monoclonal AntibodiesIBA 01/2020
1	pandemrixIBA 01/2019
1	hecolinIBA 11/2018
1	Subunit VaccinesIBA 11/2018
1	Pneumococcal Vaccines (Pneumococcal Polysaccharide Vaccine)IBA 11/2017
1	Aluminum Hydroxide (Algeldrate)FDA Link 06/2017
1	aluminum sulfate (alum)IBA 06/2017
1	rubella antibodiesIBA 01/2017
1	Human Serum Albumin FDA LinkGeneric 01/2017
1	DNA (Deoxyribonucleic Acid)IBA 04/2014
1	varicella vaccine rubella mumps measlesIBA 04/2014
1	Chickenpox Vaccine (Vaccine, Varicella)IBA 04/2014
1	AIDS VaccinesIBA 09/2013
1	Japanese Encephalitis VaccinesIBA 09/2013
1	Hepatitis A Vaccines (Hepatitis A Vaccine)IBA 09/2013
1	Conjugate VaccinesIBA 08/2012
1	AntipyreticsIBA 08/2012
1	Hepatitis B e AntigensIBA 04/2003